Bionano Genomics, Inc.
BNGO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.01 | -0.04 | 0.35 |
| FCF Yield | -209.70% | -192.77% | -29.75% | -8.69% |
| EV / EBITDA | -0.52 | -0.60 | -3.63 | -11.24 |
| Quality | ||||
| ROIC | -165.26% | -115.37% | -48.28% | -19.92% |
| Gross Margin | 1.23% | 26.49% | 21.38% | 21.54% |
| Cash Conversion Ratio | 0.62 | 0.54 | 0.94 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.45% | 26.17% | 48.42% | 21.08% |
| Free Cash Flow Growth | 45.59% | 0.97% | -74.58% | -91.54% |
| Safety | ||||
| Net Debt / EBITDA | -0.19 | -0.29 | -0.05 | 0.19 |
| Interest Coverage | -359.80 | -42.05 | -441.94 | -83.17 |
| Efficiency | ||||
| Inventory Turnover | 2.73 | 1.16 | 0.73 | 1.14 |
| Cash Conversion Cycle | 106.56 | 269.59 | 379.87 | 177.64 |